Journal
LANCET NEUROLOGY
Volume 21, Issue 1, Pages 66-77Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/S1474-4422(21)00361-6
Keywords
-
Categories
Funding
- European Commission (Marie Curie International Training Network, grant) [860197]
- JPND
- Health-Holland
- Dutch Research Council (ZonMW)
- Alzheimer Drug Discovery Foundation
- Selfridges Group Foundation
- Alzheimer Netherlands
- Alzheimer's Association
- ABOARD
- ZonMW [73305095007]
- Topsector Life Sciences Health [LSHM20106]
- Edwin Bouw Fonds
- Gieskes-Strijbisfonds
- Alzheimer Nederland [NL-17004]
- Swedish Research Council [2018-02532, 2016-00906]
- European Research Council [681712]
- Swedish State Support for Clinical Research [ALFGBG-720931]
- Alzheimer Drug Discovery Foundation, USA [201809-2016862]
- Alzheimer's disease Strategic Fund
- Alzheimer's Association [ADSF-21-831376-C, ADSF-21-831381-C, ADSF-21-831377-C]
- Olav Thon Foundation
- Erling-Persson Family Foundation
- Stiftelsen for Gamla Tjanarinnor, Hjarnfonden, Sweden [FO2019-0228]
- European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant [860197]
- UK Dementia Research Institute at UCL
- Cellectricon
- Fujirebio
- Alzecure
- Biogen
- ZonMW
- NWO
- EU-FP7
- EU-JPND
- Alzheimer Nederland
- CardioVascular Onderzoek Nederland
- Health~Holland
- Topsector Life Sciences Health
- Stichting Dioraphte
- Gieskes-Strijbis fonds
- stichting Equilibrio
- Pasman stichting
- Biogen MA
- Boehringer Ingelheim
- Life-MI
- AVID
- Roche BV
- Fujifilm
- Combinostics
- Knut and Alice Wallenberg foundation [2017-0383]
- Marianne and Marcus Wallenberg foundation [2015.0125]
- Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University
- Swedish Alzheimer Foundation [AF-939932]
- Swedish Brain Foundation [FO2019-0326]
- Parkinson foundation of Sweden [1280/20]
- Skane University Hospital Foundation [2020-O000028]
- Regionalt Forskningsstod [2020-0314]
- Swedish federal government under the ALF agreement [2018-Projekt0279]
- AVID Radiopharmaceuticals
- Eli Lilly
- Eisai
- GE Healthcare
- Pfizer
- Roche
- US National Institute on Aging [U01 AG06786, P30 AG62677, U54AG44170]
- Comunidad de Madrid [2018-T2/BMD-11885]
- San Pablo CEU University
- Marie Curie Actions (MSCA) [860197] Funding Source: Marie Curie Actions (MSCA)
Ask authors/readers for more resources
Recent research suggests that blood-based biomarkers for Alzheimer's disease may become a reality, with consistent results across different cohorts. Additionally, other blood-based biomarkers can provide information about disease progression and treatment effects.
For many years, blood-based biomarkers for Alzheimer's disease seemed unattainable, but recent results have shown that they could become a reality. Convincing data generated with new high-sensitivity assays have emerged with remarkable consistency across different cohorts, but also independent of the precise analytical method used. Concentrations in blood of amyloid and phosphorylated tau proteins associate with the corresponding concentrations in CSF and with amyloid-PET or tau-PET scans. Moreover, other blood-based biomarkers of neurodegeneration, such as neurofilament light chain and glial fibrillary acidic protein, appear to provide information on disease progression and potential for monitoring treatment effects. Now the question emerges of when and how we can bring these biomarkers to clinical practice. This step would pave the way for blood-based biomarkers to support the diagnosis of, and development of treatments for, Alzheimer's disease and other dementias.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available